Zaloguj się

Gotowe bibliografie tematyczne / Second-line therapy / Artykuły w czasopismach

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Second-line therapy.

Artykuły w czasopismach na temat „Second-line therapy”

Autor: Grafiati

Data publikacji: 2 czerwca 2025

Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Second-line therapy”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Murphy, Richard A., Henry Sunpath, Carmen Castilla, et al. "Second-Line Antiretroviral Therapy." JAIDS Journal of Acquired Immune Deficiency Syndromes 61, no. 2 (2012): 158–63. http://dx.doi.org/10.1097/qai.0b013e3182615ad1.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Calmy, Alexandra, Fernando Pascual, and Nathan Ford. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 329. http://dx.doi.org/10.1016/s0140-6736(04)16716-0.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Kulwichit, Wanla. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 329–30. http://dx.doi.org/10.1016/s0140-6736(04)16717-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Carr, Andrew. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 330. http://dx.doi.org/10.1016/s0140-6736(04)16718-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Weiss, Jared M., and Thomas E. Stinchcombe. "Second‐Line Therapy for Advanced NSCLC." Oncologist 18, no. 8 (2013): 947–53. http://dx.doi.org/10.1634/theoncologist.2013-0096.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Brandt, Kenneth D. "Second-line drug therapy for osteoarthritis." Clinical Medicine 1, no. 2 (2001): 110–12. http://dx.doi.org/10.7861/clinmedicine.1-2-110.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Martin, Mike G., Ramaswamy Govindan, and Daniel Morgensztern. "Second-line therapy for esophageal cancer." Expert Review of Anticancer Therapy 7, no. 6 (2007): 871–76. http://dx.doi.org/10.1586/14737140.7.6.871.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Hamers, Raph L. "Dolutegravir for second-line antiretroviral therapy." Lancet Infectious Diseases 19, no. 3 (2019): 218–19. http://dx.doi.org/10.1016/s1473-3099(19)30035-0.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Ahmed, Mili, Douma Rabiâa, Jarrar Emna, et al. "Second-Line Therapy in Multiple Sclerosis." Multiple Sclerosis and Related Disorders 37 (January 2020): 101586. http://dx.doi.org/10.1016/j.msard.2019.11.061.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Bachner, Mark, and Maria De Santis. "Second-line therapy in bladder cancer." Current Opinion in Urology 19, no. 5 (2009): 533–39. http://dx.doi.org/10.1097/mou.0b013e32832eb473.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Fleming, Gini F. "Second-Line Therapy for Endometrial Cancer." Obstetrical & Gynecological Survey 71, no. 7 (2016): 406–8. http://dx.doi.org/10.1097/01.ogx.0000484823.85897.c8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

Breccia, Massimo. "Nilotinib: selective inhibitor as second-line therapy." Clinical Management Issues 4, no. 6S (2015): 3–5. http://dx.doi.org/10.7175/cmi.v4i6s.1096.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Simoneaux, Richard. "Second-Line Pembrolizumab Therapy for Urothelial Cancer." Oncology Times 39, no. 10 (2017): 16–18. http://dx.doi.org/10.1097/01.cot.0000520161.64831.c7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Buosi, R., A. Gatti, S. Carnio, A. Sponghini, C. Olympios, and O. Alabiso. "Second line therapy with cetuximab in NSCLC." Journal of Clinical Oncology 24, no. 18_suppl (2006): 17145. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17145.

Pełny tekst źródła

Streszczenie:

17145 Background: EGFR is overexpressed in different solid tumors and in 50–80% of NSCLC. The neoplastic growth and metastatic process is correlated with EGFR overexpression, so that it became the target of a new therapeutic approach. The monoclonal antibody (Mab) against the extracellular domain represent the most innovated method of EGFR inaction. Methods: From May to October 2005 10 patients (8 M and 2 F) of median age 62 years with NSCLC in stage IIIB-IV (7 adenocarcinomas and 3 squamocellulars) have been treated with the association of chemotherapy and Cetuximab. All patients presented a

Style APA, Harvard, Vancouver, ISO itp.

15

Gisbert, Javier P. "Review: Second-line rescue therapy ofHelicobacter pyloriinfection." Therapeutic Advances in Gastroenterology 2, no. 6 (2009): 331–56. http://dx.doi.org/10.1177/1756283x09347109.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Wood, Alastair J. J., Joseph M. Cash, and John H. Klippel. "Second-Line Drug Therapy for Rheumatoid Arthritis." New England Journal of Medicine 330, no. 19 (1994): 1368–75. http://dx.doi.org/10.1056/nejm199405123301908.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Sasako, Mitsuru. "Ramucirumab: second-line therapy for gastric cancer." Lancet Oncology 15, no. 11 (2014): 1182–84. http://dx.doi.org/10.1016/s1470-2045(14)70464-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Price, Timothy J. "Second-line therapy for metastatic colorectal cancer." Lancet Oncology 16, no. 5 (2015): 476–77. http://dx.doi.org/10.1016/s1470-2045(15)70169-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Ibañez, Patricio, E. Glasinovic, M. Gatica, Paula Vial, Eduardo Valdivieso, and Roque Saenz. "Inmunomodulation in Ulcerative Colitis. Second Line Therapy?" Gastrointestinal Endoscopy 65, no. 5 (2007): AB259. http://dx.doi.org/10.1016/j.gie.2007.03.606.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Chong, Geoff, and David Cunningham. "Second-line therapy for advanced colorectal cancer." Current Colorectal Cancer Reports 1, no. 1 (2005): 7–12. http://dx.doi.org/10.1007/s11888-005-0010-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Ritter, Timothy E., Chris Fourment, Samantha A. Kuten, Thomas C. Hardin, and Lucinda J. Van Anglen. "728 Second-Line Biologic Therapy After Vedolizumab." American Journal of Gastroenterology 114, no. 1 (2019): S429—S430. http://dx.doi.org/10.14309/01.ajg.0000592448.04563.6a.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

WILLIAMS, H. JAMES. "COMBINATION SECOND-LINE THERAPY FOR RHEUMATOID ARTHRITIS." Rheumatology 33, no. 7 (1994): 603–4. http://dx.doi.org/10.1093/rheumatology/33.7.603.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Martin, M. G., A. Wang-Gillam, M. A. Waqar, et al. "Second-line systemic therapy for esophageal cancer." Journal of Clinical Oncology 26, no. 15_suppl (2008): 15623. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.15623.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Starling, Naureen, and David Cunningham. "Second-line therapy for advanced colorectal carcinoma." Current Oncology Reports 7, no. 3 (2005): 173–80. http://dx.doi.org/10.1007/s11912-005-0070-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Savchenko, I. V., V. V. Breder, I. S. Stilidi, et al. "Second line drug therapy for biliary cancer." Meditsinskiy sovet = Medical Council, no. 22 (December 6, 2022): 136–47. http://dx.doi.org/10.21518/2079-701x-2022-16-22-136-147.

Pełny tekst źródła

Streszczenie:

Biliary cancer is a group of tumors that develop from the epithelium of the intra- and extrahepatic bile ducts (cholangiocarcino-ma), as well as the gallbladder. For 10 years, chemotherapy based on a combination of gemcitabine and cisplatin has remained the standard of first-line therapy in patients with locally advanced or metastatic biliary cancer, resulting in a median overall survival of 11.7 months. With the progression of the disease on the first line, effective options did not previously exist. Attempts to use various chemotherapeutic regimens, both in monotherapy and in combination, ha

Style APA, Harvard, Vancouver, ISO itp.

26

Patrikar, Seema, Subramanian Shankar, Atul Kotwal, et al. "Predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy." Medical Journal Armed Forces India 73, no. 1 (2017): 5–11. http://dx.doi.org/10.1016/j.mjafi.2016.09.008.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Dzhanyan, I. A., V. V. Breder, O. I. Borisova та K. K. Laktionov. "Рembrolizumab as second line therapy for hepatocellular patient". Meditsinskiy sovet = Medical Council, № 20 (12 грудня 2021): 150–54. http://dx.doi.org/10.21518/2079-701x-2021-20-150-154.

Pełny tekst źródła

Streszczenie:

The optimal hepatocellular cancer (HCC) therapy remains a challenge. Due to checkpoint inhibitors patients with intolerance to the targeted therapy and or those with the impaired liver function can get an appropriate drug therapy. This clinical observation illustrates the long-term effect of pembrolizumab as the 2-line therapy in a patient diagnosed with. Sorafenib in standard doses as first line therapy led to severe toxicity and necessitated the withdrawal of therapy. Although subsequently the doses were reduced and concomitant medications used, sorafenib therapy was discontinued due to pron

Style APA, Harvard, Vancouver, ISO itp.

28

Lambert, Michele P. "Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia." Hämostaseologie 39, no. 03 (2019): 266–71. http://dx.doi.org/10.1055/s-0039-1684032.

Pełny tekst źródła

Streszczenie:

AbstractManagement of immune thrombocytopenia (ITP) is complex requiring communication between patients and caregivers to establish a mutual understanding of the impact of the patient's disease on quality of life, the current symptoms and risk of morbidity/mortality and the goals of therapy. The currently available second-line therapies for ITP provide potential for management of thrombocytopenia and bleeding symptoms with medical therapy or surgical intervention potentially offering long-term remission. All therapies are associated with potential side effects and necessary monitoring or modif

Style APA, Harvard, Vancouver, ISO itp.

29

Chaudhury, Bobby, and John Grainger. "UK second-line paediatric primary ITP therapy analysis." Archives of Disease in Childhood 106, no. 9 (2021): 929.1–931. http://dx.doi.org/10.1136/archdischild-2020-320646.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Raja, T. "Optimizing second-line therapy for chronic myeloid leukemia." Indian Journal of Cancer 49, no. 1 (2012): 46. http://dx.doi.org/10.4103/0019-509x.98918.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

&NA;. "Felbamate stays - but only as second-line therapy." Inpharma Weekly &NA;, no. 960 (1994): 21. http://dx.doi.org/10.2165/00128413-199409600-00044.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

&NA;. "Long-term second line therapy in rheumatoid arthritis." Inpharma Weekly &NA;, no. 971 (1995): 17. http://dx.doi.org/10.2165/00128413-199509710-00042.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

&NA;. "Prescribing second-line therapy for RA in France." Inpharma Weekly &NA;, no. 1327 (2002): 5. http://dx.doi.org/10.2165/00128413-200213270-00010.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

&NA;. "Trimetrexate second-line therapy for AIDS-related PCP?" Inpharma Weekly &NA;, no. 1010 (1995): 5. http://dx.doi.org/10.2165/00128413-199510100-00010.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Schmittel, Alexander. "Second-line therapy for small-cell lung cancer." Expert Review of Anticancer Therapy 11, no. 4 (2011): 631–37. http://dx.doi.org/10.1586/era.11.7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

&NA;. "Methotrexate - second-line therapy for superficial bladder cancer?" Inpharma Weekly &NA;, no. 892 (1993): 14. http://dx.doi.org/10.2165/00128413-199308920-00031.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

&NA;. "Felbamate stays ??? but only as second-line therapy." Reactions Weekly &NA;, no. 524 (1994): 2. http://dx.doi.org/10.2165/00128415-199405240-00002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Gerullis, Holger, Thomas Otto, and Thorsten H. Ecke. "Targeted agents in second-line bladder cancer therapy." Anti-Cancer Drugs 23, no. 10 (2012): 1003–15. http://dx.doi.org/10.1097/cad.0b013e3283582a33.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Currie, Graeme P., and Sudip Saha. "What About Add-On Second-Line Controller Therapy?" Chest 127, no. 3 (2005): 1077–78. http://dx.doi.org/10.1378/chest.127.3.1077.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Porter, D. R., I. McInnes, J. Hunter, and H. A. Capell. "Outcome of second line therapy in rheumatoid arthritis." Annals of the Rheumatic Diseases 53, no. 12 (1994): 812–15. http://dx.doi.org/10.1136/ard.53.12.812.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Pérez-Valero, Ignacio, and José R. Arribas. "Second-line antiretroviral therapy and the human factor." Lancet HIV 2, no. 2 (2015): e34-e35. http://dx.doi.org/10.1016/s2352-3018(15)00003-x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Heath, Vicky. "Second-line therapy for adrenocortical carcinoma proves beneficial." Nature Reviews Endocrinology 6, no. 7 (2010): 355. http://dx.doi.org/10.1038/nrendo.2010.76.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Wachter, Kerri. "Vorinostat fails as second-line therapy for mesothelioma." Community Oncology 8, no. 10 (2011): 459. http://dx.doi.org/10.1016/s1548-5315(12)70150-x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

BATES, BETSY. "Bleomycin as Second Line Therapy Clears Cancerous Lesions." Skin & Allergy News 39, no. 7 (2008): 30. http://dx.doi.org/10.1016/s0037-6337(08)70481-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

MECHCATIE, ELIZABETH. "Panel Backs Romidepsin as Second-Line CTCL Therapy." Skin & Allergy News 40, no. 10 (2009): 8. http://dx.doi.org/10.1016/s0037-6337(09)70478-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Bex, Axel. "Prognostic accuracy in second-line renal cancer therapy." Lancet Oncology 16, no. 3 (2015): 240–41. http://dx.doi.org/10.1016/s1470-2045(15)70009-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Gourd, Elizabeth. "Promising new second-line therapy for Hodgkin lymphoma." Lancet Oncology 20, no. 2 (2019): e76. http://dx.doi.org/10.1016/s1470-2045(19)30016-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Timcheva, C. "Second-line targeted therapy of gastrointestinal stromal tumours." memo - Magazine of European Medical Oncology 3, no. 2 (2010): 61–64. http://dx.doi.org/10.1007/s12254-010-0196-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Bird, H. A. "Long-term second-line therapy in rheumatoid arthritis." Clinical Rheumatology 4, no. 2 (1985): 121–23. http://dx.doi.org/10.1007/bf02032281.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Zustovich, Fable, Giuseppe Lombardi, Ornella Nicoletto, and Davide Pastorelli. "Second-line therapy for refractory renal-cell carcinoma." Critical Reviews in Oncology/Hematology 83, no. 1 (2012): 112–22. http://dx.doi.org/10.1016/j.critrevonc.2011.08.008.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!